Takeda Pharmaceutical Company Limited announced plans to invest €40m in a new facility at their Grange Castle site in Dublin.
This Investment by Takeda will expand their Grange Castle site’s existing footprint, with the construction of a new standalone high containment production facility dedicated to manufacturing its oncology product NINLAROTM for global markets. The investment will create approximately 40 new jobs.
This investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site, said Paul Keogh, Plant Director at Takeda Ireland Grange Castle.
|Name||Takeda Pharmaceutical Company Limited|
|Type||New Production Facility|
|Estimated Cost||€40 Million|